Abivax (HAM:2X10) EV-to-OCF: -42.93 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:2X10 Abivax SA HAM:2X10
30 GF Score
Price €89.00
! 1 Warning Sign
View Full Analysis

What is Abivax EV-to-OCF?

Abivax HAM:2X10 +4.05% 30 EV-to-OCF is -42.93 as of Sep. 22, 2026. GuruFocus rates HAM:2X10 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,403 Biotechnology companies, Abivax ranks better than 91.09% on this metric.

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Abivax's Enterprise Value is €7,449.99 Mil. Abivax's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €-173.53 Mil. Therefore, Abivax's EV-to-OCF for today is -42.93.

The historical rank and industry rank for Abivax's EV-to-OCF or its related term are showing as below:

HAM:2X10' s EV-to-OCF Range Over the Past 10 Years
Min: -46.81   Med: 0   Max: -46.81
Current: -46.81

During the past 13 years, the highest EV-to-OCF of Abivax was -46.81. The lowest was -46.81. And the median was .

HAM:2X10's EV-to-OCF is ranked better than
91.09% of 1403 companies
in the Biotechnology industry
Industry Median: -3.36 vs HAM:2X10: -46.81

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-09-22), Abivax's stock price is €89.00. Abivax's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.523. Therefore, Abivax's PE Ratio (TTM) for today is At Loss.


Abivax  (HAM:2X10) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Abivax's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=89.00/-4.523
=At Loss

Abivax's share price for today is €89.00.
Abivax's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.523.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Abivax EV-to-OCF Related Terms


Abivax EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Abivax's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax EV-to-OCF Chart

Abivax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-OCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 -0.21 -2.12 -2.59 -46.18

Abivax Quarterly Data
Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-OCF -10.38 -13.59 -70.65 -54.00 -41.34

HAM:2X10 vs VRTX, REGN, MRNA: EV-to-OCF Comparison

For the Biotechnology subindustry, Abivax's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abivax EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Abivax's EV-to-OCF falls into.


HAM:2X10
30GF Score
Abivax SA HAM:2X10
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abivax EV-to-OCF Calculation

Abivax's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=7449.992/-173.52974498526
=-42.93

Abivax's current Enterprise Value is €7,449.99 Mil.
Abivax's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-173.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-OCF →
What does a EV-to-OCF of -42.93 mean?
Abivax (HAM:2X10) has a EV-to-OCF of -42.93 as of Sep. 22, 2026. According to the industry distribution chart, Abivax ranks #125 out of 1403 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Abivax's EV-to-OCF too high?
Abivax's current EV-to-OCF is -42.93. Based on the distribution chart, Abivax ranks #125 out of 1403 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abivax has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Abivax's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abivax ranks #125 out of 1403 companies for EV-to-OCF. This places Abivax in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Abivax's current EV-to-OCF is -42.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abivax stock overvalued right now?
Abivax (HAM:2X10) has a current EV-to-OCF of -42.93. The current EV-to-OCF is -42.93. Abivax's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Abivax (HAM:2X10), the current EV-to-OCF is -42.93 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abivax Business Description

Address 7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
30GF Score

Get the complete analysis for HAM:2X10

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€89.00
Price